Skip to main content

Regulatory and Washington

  • FDA approves J&J HIV drug in children

    TITUSVILLE, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating HIV in children.

    J&J's Janssen Therapeutics division announced Tuesday the FDA approval of Intelence (etravirine) in patients ages 6 years to younger than 18 years with HIV-1 who have taken other therapies but whose infection has become resistant to treatment. The drug already was approved for adults.

  • Supreme Court hears arguments surrounding healthcare law

    WASHINGTON — The U.S. Supreme Court justices have gathered this week to discuss a potential legal issue surrounding President Obama's healthcare law.

  • Ninth Circuit Court of Appeals denies attempt to reinstate Medi-Cal cuts

    ALEXANDRIA, Va. — The Ninth Circuit Court of Appeals ruled in favor of healthcare providers, denying a request by the California Department of Health Care Services to suspend a preliminary injunction that currently is preventing the implementation of Medi-Cal cuts.

  • Suppliers, FDA shine spotlight on switches

    The recent Food and Drug Administration public meeting on driving future switch potential by way of the pharmacist and/or health technology sparked some discussion on what’s next.


  • FDA approves Teva allergy drug

    JERUSALEM — The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

    Teva announced the approval of Qnasl (beclomethasone dipropionate) for seasonal and year-round nasal allergies in patients ages 12 years and older. The company said the drug, a "dry" nasal aerosol, would become available next month.

  • Report: Metformin cost-effective strategy in battling diabetes

    ALEXANDRIA, Va. — Lifestyle intervention and treatment with metformin provide safe, long-term, cost-effective means of preventing Type 2 diabetes and should be incorporated into prevention strategies for reducing the dramatic rise in incidence of Type 2 diabetes in the United States, according to two new analyses and an editorial published in the April issue of Diabetes Care.

  • Increase in Rx costs surpasses inflation rate

    Increases in the prices of prescription drugs have far outpaced the rate of general inflation over the years, as increases in the prices of branded and specialty drugs have offset decreases in the prices of generics, according to a new report by AARP’s research arm.


    The study, conducted by AARP’s Public Policy Institute, found that the cumulative change in drug prices from 2005 to 2009 was almost double the rate of inflation. As a result, the average annual cost of drug therapy continued to rise.


  • Court dismisses AstraZeneca case against FDA

    NEW YORK — A federal court has dismissed a case that drug maker AstraZeneca filed against regulators regarding a drug used to treat psychotic and bipolar disorders, the company said Monday.

X
This ad will auto-close in 10 seconds